CPT-Pharmacometrics & Systems Pharmacology

Papers
(The H4-Index of CPT-Pharmacometrics & Systems Pharmacology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load132
Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling53
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility47
Mini‐Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study36
Physiologically‐based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%35
An artificial neural network−pharmacokinetic model and its interpretation using Shapley additive explanations34
QSP‐IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno‐Oncology Applications32
Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs25
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients24
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations23
A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach22
Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain22
Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration22
Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling22
Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically‐based pharmacokinetic model22
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability21
Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator21
Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T20
A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans20
Opportunities and challenges for applying model‐informed drug development approaches to gene therapies20
0.053202867507935